ACTIVE_NOT_RECRUITING

Pro-active Genetic Testing in Kidney Transplant Patients

NCT05298904•Mayo Clinic

Summary

The purpose of this study is to determine the prevalence of genetic mutations that increase the risk of cancer and other medically actionable diseases in kidney transplant patients and to assess the impact of genetic testing on subsequent surveillance for cancer.

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•\- Post transplant Kidney and Kidney Pancreas recipients.

Exclusion Criteria

•Simultaneous Liver Kidney Transplant.
•Simultaneous Heart Kidney Transplant.
•Non renal transplant history.

Locations (1)

Mayo Clinic Arizona

Scottsdale, Arizona, United States

Key Dates

Start Date

March 28, 2022

Primary Completion Date

March 1, 2037

Completion Date

March 1, 2038

Last Updated

January 27, 2026

Enrollment

177

ACTUAL participants

Conditions

Kidney Transplant

Interventions

Genetic Health Screen Panel

DIAGNOSTIC_TEST

Pilot Trial of Supplemental Vitamin A and Nicotinamide

NCT05702398

Skin CancerKidney Transplant Recipients

View study

RECRUITINGNA

Parathyroidectomy After Kidney Transplantation

NCT07415421

HyperparathyroidismKidney Transplantation Recipients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGNA